
USFDAJul 7, 2026, 12:56 PM
Vera Therapeutics' TRUTAKNA gets FDA accelerated approval
AI Summary
Vera Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for TRUTAKNA™ (atacicept-vymj). This approval is specifically for reducing proteinuria in adult patients diagnosed with primary immunoglobulin A nephropathy who are at risk for disease progression.
Key Highlights
- Vera Therapeutics' TRUTAKNA™ (atacicept-vymj) received accelerated approval from the U.S. FDA.
- The approval is for reducing proteinuria in adults with primary immunoglobulin A nephropathy.
- The drug targets patients at risk for disease progression.
Price Impact
More from VERA
Quarterly ResultNov 5, 4:15 PM
Vera Therapeutics Q3 Revenue $10.3M; Net Loss $93.7M; TRUTAKNA Launch Underway
Business UpdateOct 20, 8:02 AM
Vera Therapeutics Announces Upcoming Investor Webcasts for Clinical Trial Results and Q3 Financials
Clinical TrialSep 15, 6:56 AM
Vera Therapeutics: TRUTAKNA Meets All Endpoints in IgAN Trial